Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany

Rheumatology

Volumn 49, Issue 11, 2010, Pages 2122-2134

  Neilson, Aileen R ^a   Sieper, Joachim ^b   Deeg, Maria ^c  

^a HealthEcon Ltd   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Wyeth Pharma GmbH   (Germany)

Author keywords

Ankylosing spondylitis; Cost effectiveness; Cost utility; Economic evaluation; Quality of life; Tumour necrosis factor

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOPROSTHESIS; FEMALE; GERMANY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTICENTER STUDY; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PHYSIOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL INSURANCE; SOCIETY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; GERMANY; HEALTH CARE COSTS; HUMANS; IMMUNOGLOBULIN G; MALE; MODELS, THEORETICAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

EID: 78649396053     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq222     Document Type: Article

References (54)

1. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. for the ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rhuem Dis 2006;65:316-20.
2. Keat A, Barkham N, Bhalla A et al. BSR Guidelines for prescribing TNF alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology 2005;44:939-47.
3. Kobelt G, Andlin-Sobocki P, Maksymowych WP. Costs and quality of life of patients with ankylosing spondylitis in Canada. J Rheumatol 2006;33:289-95.
4. Wailoo A, Bansback N, Chilcott J. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance. Rheumatology 2008;47:119-20.
5. Ara RM, Reynolds V, Conway P. The cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in the UK. Rheumatology 2007;46:1338-44.
6. Boonen A, van der heijde D, Severens J, Boemdermaker A, Landewe R. Markov model into the cost-utility over 5 years of etanercept and ifliximab compared to usual care in patients with active ankylosing spondylitis. Ann Rheum Dis 2006;65:201-8.
7. Botteman MF, Hay JW, Luo MP, Curry AS, Wong RL, van Hout BA. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kindgom. Rheumatology 2007;46:1320-8.
8. Kobelt G, Sobocki P, Sieper J, Braun J. A comparison of the cost-effectiveness of infliximab in the treatment of anklosing spondylitis in UK based on two different clinical trials. Int J Technol Assess Health Care 2007;23:368-75.
9. Kobelt G, Andlin-Sobocki P, Brophy S, Jönsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade®). Rheumatology 2004;43:1158-66.
10. Kobelt G, Sobocki P, Mulero J, Gratacos J, Collantes-Estevez E, Braun J. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice. Scand J Rheumatol 2008;37:62-71.
11. Kobelt G, Andlin-Sobocki P, Maksymowch WP. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006;33:732-40.
12. Drummond M, Barbieri M, Cook J et al. Transferability of economic evaluations across jurisdictions. Value Health 2009;12:409-18.
13. Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004;22:857-76.
14. Garret S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 1994;1:2286-91.
15. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol 1994;21:2281-5.
16. Van der Heijde D, Da Silva JC, Dougados M et al. Once-weekly 50-mg dosing of etanercept is as effective as twice-daily dosing in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:1572-7.
17. Davis JC, van der Heijde D, Braun et al. Recombinant tumour necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 2003;48:3230-6.
18. Davis JC, van der Heijde D, Braun J. Sustained durability and tolerability of etanercept in ankylosing spondylitis for weeks. Ann Rheum Dis 2005;64:1557-62.
19. Davis JC, van der Heijde, Braun J et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52.
20. Methods for assessments of the relation of benefit to costs in the German Statutory Health Care System. Institute for Quality and Efficiency in Health Care (IQWIG). Version 1.1 09.10.20998. http://www.iqwig.de/download/08-10-14_Methods_of_the_Relation_of_Benefit s_to_Costs_v_1_1.pdf (6 July 2010, date last accessed).
21. von der Schulenburg JMG, Greiner W, Jost F et al. The Hanover Consensus Group. German recommendations on health economic evaluation: third and updated version of the Hanover consensus. Value Health 2008;11:539-44.
22. Sieper J, Dijkmans BAC, Van der Linden S, Martin Mola E. Long term efficacy and safety of etanercept in patients with ankylosing spondylitis: 148 to 160 week analysis from an ongoing trial. EULAR Meeting Abstracts 2006;65:437.
23. Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A. German Collaborative Arthritis Centres. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006;65:1175-83.
24. Data from the national database of the German collaborative arthritis centres for 2007. Data specially commissioned for the current analysis. http://www.drfz.de/index.php?id=22&L=5 (6 July 2010, date last accessed).
25. Tahir H, Moore S, Ehrenstein MR. Comparison of anti-TNF therapy in daily practice. Poster Abstract. BSR 2005;44(Suppl. 1):i2-i172.
26. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice. Results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. Arthritis Rheum 2006;4:600-6.
27. Robertson LP, Davis MJ. A longitudinal study of disease activity and functional status in a hospital cohort of patients with ankylosing spondylitis. Rheumatology 2004;43:1565-8.
28. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993;52:174-6.
29. Simmonds DPM. Mortality in ankylosing spondylitis. Rheum Europe 1996;4:15-6.
30. Rote Liste® Service GmbH, Drugs List of Germany (incl. EU-licensed and certain medical products and devices), Frankfurt/Main, 2008. http://www.rote-liste.de (6 July 2010, date last accessed).
31. Deutsche Bundesbank Exchange Rate Statistics January 2010. Statistical Supplement to the Monthly Report 5. Deutsche Bundesbank Eurosystem. Wilhelm-Epstein-Strasse 1460431 Frankfurt am Main, Germany. http://www.bundesbank.de/statistik/statistik_veroeffentlichungen_beiheft 5.en.php (6 July 2010, date last accessed).
32. KBV: EBM;V.7.0. www.kbv.de (16 October 2008, date last accessed).
33. Statistisches Bundesamt 2007. http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/DE/Co ntent/Statistiken/Zeitreihen/WirtschaftAktuell/Basisdaten/Content100/vpi 102a.psml (6 July 2010, date last accessed).
34. Zink A, Listing J, Klindworth C, Zeidler H. for the German Collaborative Arthritis Centres. The national database of the German Collaborative Arthritis Centres: I. Structure, aims and patients. Ann Rheum Dis 2001;60: 199-206.
35. Briggs A, Gray A. The distribution of healthcare costs and their statistical analysis for economic evaluation. J Health Serv Res Policy 1998;3:233-45.
36. Brandt J, Listing J, Haibel H et al. Long-term efficacy and safety after readministration in patients with active ankylosing spondylitis. Rheumatology 2005;44:342-8.
37. Brandt J, Khariouzov A, Listing J et al. Six months results of a German double-blind placebo controlled, phase-III clinical trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
38. Schulze-Koops H, Deeg M, Runge C, Volmer T, Brecht JG. Cost-effectiveness of etanercept in combination with MTX in comparison with MTX in the treatment of active rheumatoid arthritis in Germany. Congress of the German Society for Rheumatology, 24-27 September, Berlin. http://www.dgrh.de/fileadmin/media/Die_DGRH/Jahreskongresse/Abstracts_20 08_PDFs/K08_RA1.15.pdf (6 July 2010, date last accessed).
39. Schulze-Koops H, Deeg M, Runge C, Volmer T, Brecht JG. [Health-economic assessment of combination therapy for rheumatoid arthritis with methotrexat and etanercept based on the TEMPO Study]. Z Rheumatol 2009;68:836-41.
40. Rubbert A, Wolka D, Ladinek G, Kirchhoff T, Kielhorn A, Merkesdal S. Cost utility analysis of rituximab in patients with rheumatoid arthritis after previous TNF alpha blocker treatment failure 2008. http://www.dgrh.de/fileadmin/media/Die_DGRH/Jahreskongresse/Abstracts_20 08_PDFs/K08_KR.07.pdf (6 July 2010, date last accessed).
41. Boonen A, Maetzel A, Drummond M et al. The OMERACT imitative. Towards a reference approach to derive QALY for economic evaluations in rheumatology. J Rheumatol 2009;36:2045-9.
42. National Institute for Health and Clinical Excellence (NICE). Updated Guide to the Methods of Technology Appraisal. 2008. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf (6 July 2010, date last accessed).
43. Uhlig T, Garrat A. Using utilities. J Rheumatol 2010;37:223-5.
44. Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ 2009;10:357-9.
45. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52.
46. Merkesdal S, Kirchhoff T, Wolka D, Ladinek G, Kielhorn A, Rubbert-Roth A. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis and etanercept failure. Eur J Health Econ 2010;11:95-104.
47. Benucci M, Li Gobbi F, Sabadini L, Saviola G, Baiardi P, Manfredi M. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients. Int J Immunopathol Pharmacol 2009;22:1147-52.
48. Hallinen TA, Soini EJO, Eklund K, Puolakka K. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology Advance Acess Published January 25, 2010, doi:10.1093/rheumatology/kep425.
49. Kulp W, Corzillius M, Greiner W et al. Value of tumour necrosis factor-alpha-antagonists in the treatment of rheumatoid arthritis. Arthritis - Health Technology Assessment, 2005. http://portal.dimdi.de/de/hta/hta_berichte/hta075_bericht_de.pdf (6 July 2010, date last accessed).
50. Nord E, Daniels N, Kamlet M. QALYs: some challenges. Value Health 2009;12(Suppl. 1):S10-5.
51. Ariza-Ariza R, Hernández-Cruz B, Navarro-Sarabia F. Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 2003;49:483-7.
52. Oldroyd J, Schachna L, Buchbinder R et al. Ankylosing spondylitis patients commencing biologic therapy have high baseline levels of comorbidity: a report from the Australian rheumatology association database. Int J Rheumatol Advance Access published August 2, 2009, doi:268569.
53. Bansback N, Maetzel A, Drummond M et al. Considerations and preliminary proposals for defining a reference case for economic evaluations in ankylosing spondylitis. J Rheumatol 2007;34:1178-83.
54. Pavelka K, ForejtováS, Stolfa J et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. Clin Exp Rheumatol 2009;27:958-63.